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Abstract
Background: Treatment monitoring of drug-resistant tuberculosis (DR-TB) in resource-limited settings is
challenging. We developed a multi-analyte assay for eleven anti-TB drugs in small hair samples as an objective
metric of drug exposure.
Methods: Small hair samples were collected from participants at various timepoints during directly observed RR-TB
treatment at an inpatient tertiary referral facility in South Africa (DR-TB cohort). We assessed qualitative
determination (i.e., detection above limit of detection) of bedaquiline, linezolid, clofazimine, pretomanid,
levofloxacin, moxifloxacin, pyrazinamide, isoniazid, ethambutol, ethionamide, and prothionamide in an LC-MS/MS
index panel assay against a reference standard of inpatient treatment records. Because treatment regimens prior to
hospitalization were not available, we also analyzed specificity (for all drugs except isoniazid) using an external
cohort of HIV-positive patients treated for latent TB infection with daily isoniazid (HIV/LTBI cohort) in Uganda.
Results: Among the 57 DR-TB patients (58% with pre-XDR/XDR-TB; 70% HIV-positive) contributing analyzable hair
samples, the sensitivity of the investigational assay was 94% or higher for all drugs except ethionamide (58.5, 95%
confidence interval [CI], 40.7–99.9). Assay specificity was low across all tested analytes within the DR-TB cohort;
conversely, assay specificity was 100% for all drugs in the HIV/LTBI cohort.
Conclusions: Hair drug concentrations reflect long-term exposure, and multiple successive regimens commonly
employed in DR-TB treatment may result in apparent false-positive qualitative and falsely elevated quantitative hair
drug levels when prior treatment histories within the hair growth window are not known.
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Background
An estimated 1.5 million people globally have rifampin-
resistant tuberculosis (RR-TB). Treatment of RR-TB in
the setting of HIV co-infection is complicated by high
pill burden [1], overlapping drug toxicities [2], poor drug
absorption [3, 4], and high mortality [5]. Because of
non-invasive collection, easy storage, and long-term
detection window, hair concentrations of anti-TB medi-
cations represent an important objective determination
of patient adherence and a measure of individual
pharmacodynamics.
Determination of drug concentrations in small hair
samples has long informed forensic investigation and
environmental exposure assessment, where the liquid
chromatography- tandem mass spectrometry (LC-MS/
MS) measures are considered highly sensitive and spe-
cific. Assuming a scalp hair growth rate of approximately
1 cm per month, historic drug exposure can be ascer-
tained via segmental analysis, determining drug levels in
various sections of hair with successive distance from
the root [6]. Stringent in vitro validation procedures pro-
vide international guidance for method development [7],
though real-world assessments occasionally lead to false-
positive (e.g., external contamination) or false-negative
(e.g., cosmetic hair treatments) results.
Recently, we developed and validated a multi-drug
assay panel for measuring eleven anti-tuberculosis drug
concentrations in small hair samples [8, 9]. Here, we
report a clinical diagnostic accuracy study of qualitative
results for individual drugs (as determined by detection
above the assay’s limit of detection (LOD)) as measured
against a gold standard of inpatient treatment adminis-
tration records in a routine care setting in South Africa.
In a post-hoc assessment, we validated assay specificity
within an external cohort of patients receiving isoniazid
alone for latent TB infection (LTBI) where ingestion of
drugs used to treat RR-TB would be highly improbable.
Methods
Study population and sample collection
The primary study cohort of adult (aged ≥ 18 years) pa-
tients with MDR-, pre-XDR, and XDR-TB was recruited
as a convenience sample from July 12, 2016 to Decem-
ber 6, 2017 at Brooklyn Chest Hospital (BCH), an
inpatient referral facility for drug-resistant TB in Cape
Town, Western Cape, South Africa. During the study
period, pre-XDR and XDR-TB patients were treated with
24 weeks of bedaquiline within an optimized, individual-
ized background regimen that could include levofloxa-
cin, linezolid, and/or clofazimine. Inpatient treatment
was administered by directly observed treatment (DOT);
treatment administered prior to the hospital stay was ad-
ministered according to programmatic standards at each
peripheral clinic, which may or may not have included
DOT. Small hair samples were collected as previously
described [8] at a single time point during the patient’s
final treatment regimen (i.e., prior to last known treat-
ment outcome). Patients with cosmetically treated hair
(including bleaching) or whose scalp hair was less than
or equal to 2 mm in length were excluded.
A secondary study cohort of adult HIV-positive
patients on ART with LTBI was enrolled in a longitu-
dinal cohort study at the Mbarara Regional Referral
Hospital in Uganda. The participants in this study had
LTBI confirmed by tuberculin skin testing (≥5 mm
induration) with active and prior TB and TB drug expos-
ure ruled out; all participants were given daily self-
administered 300mg INH. This cohort was chosen for a
specificity analysis of our multi-analyte assay given the
low likelihood of exposure to second-line anti-TB medi-
cations but high HIV prevalence. In this secondary
cohort, hair was collected after 3 and 6 months of INH
and analyzed at both timepoints when available.
Small hair samples were collected using previously
described methods [10]. Briefly, from all participants
with scalp hair and who consented for hair collection,
20–30 strands of hair were cut from the occipital
region. The distal end of the hair sample was marked
with a small piece of tape to denote directionality,
and the hair was stored in aluminum foil at room
temperature. Each participant provided written
informed consent, and ethical approval was obtained
from the University of Cape Town Human Research
Ethics Committee (187/2016), the Mbarara University
of Science and Technology Research Ethics Commit-
tee (11/10–16), and the University of California, San
Francisco (UCSF) Human Research Protection Pro-
gram (14–14,609). All hair samples were analyzed at
the UCSF TB Hair Analysis Laboratory.
Investigational LC-MS/MS assay
We analyzed the samples using our validated LC-MS/
MS method for the simultaneous quantitation of eleven
MDR-TB drugs in small hair samples [11]. Briefly, hair
strands (~ 20–30 cut to 3 cm and weighed to 2 mg) were
pulverized and extracted with methanol. The hair extract
was reconstituted to water with 1% formic acid before
injection into the Agilent LC 1260 (Agilent Technolo-
gies, Sta. Clara, CA) attached to an AB Sciex API 5500
mass spectrometer (AB Sciex, Foster City, CA). The ana-
lytes were separated by gradient elution on a Phenom-
enex Synergi Polar RP column (2.1 × 100, 2.5 μm particle
size, Phenomenex, Torrance, CA) using water with 1%
formic acid as mobile phase A (MPA) and acetonitrile
with 0.1% formic acid as mobile phase B (MPB).
Ionization of each analyte in the mass spectrometer was
achieved using electrospray ionization (ESI) in positive
polarity, and mass scanning was performed via multiple
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reaction monitoring (MRM). Quantification of each ana-
lyte was performed by isotope dilution method using
deuterated, 15N- or 13C-labeled isotopologue of each
drug standard. Data analysis was done using AB Sciex
Analyst 1.6 and AB Sciex MultiQuant 2.1 (AB Sciex,
Foster City, CA) software packages. Diagnostic specifi-
city was also monitored during method validation using
hair samples from laboratory members who have not
taken any of the drugs in the panel [9].
Statistical analysis
The primary objective of the study was to determine the
sensitivity and specificity of the investigational assay ana-
lyzing qualitative hair concentrations of INH, pyrazina-
mide (PZA), ethambutol (EMB), levofloxacin (LFX),
moxifloxacin (MFX), linezolid (LZD), clofazimine (CFZ),
bedaquiline (BDQ), pretomanid (PTM), ethionamide
(ETH), and prothionamide (PTH), against a reference
standard of known drug administration, according to
data abstracted from inpatient treatment records. In the
primary analyses, the reference standards for sensitivity
and specificity were considered differently. For sensitiv-
ity, the reference standard was considered ‘positive’ if
the drug was taken for at least 14 days during the hair
growth window. The hair growth window was defined as
the interval from 94 to 5 days prior to hair collection.
Due to prolonged half-lives, the hair growth window was
defined as an interval beginning 800 and 420 days prior
to hair collection for BDQ and CFZ, respectively (i.e., a
time period encompassing roughly five half-lives). For
specificity, the reference standard was considered ‘nega-
tive’ if the drug is not taken for any days in the previous
124 days prior to and including the day of hair collec-
tion. Because of the long half-lives of BDQ and CFZ, the
reference standard was ‘negative’ if there was no known
history of past use of these drugs at any time. Specificity
was also calculated separately using a secondary, exter-
nal cohort described above. Investigational assay analysis
was performed independently of reference standard
treatment data. The binomial exact method was used to
calculate 95% confidence intervals using Stata 14.2 [12].
Results
Participants
A total of 111 participants with DR-TB were enrolled
from July 12, 2016 to December 6, 2017 (Fig. 1). Among
54 participants (49%), directionality of the hair sample
(i.e., differentiation of distal and proximal hair segments)
could not be reliably determined. Thus, 57 participants
with MDR/XDR-TB were eligible for inclusion in the
study. These participants were predominantly female
(98%, n=56/57) and HIV-positive (70%, n=40/57; 95%
(n=38/40) on ART). A broad spectrum of phenotypic
resistance patterns was represented, and participants had
been on treatment for a median of 144 days (interquar-
tile range (IQR) 50–337 days) prior to hair sampling
(Table 1). The LTBI samples (n=28, from 19 persons)
were collected from 42% females; all were HIV-positive
and all were on ART. The total number of patients
approached but declining to participate was not
recorded.
Investigational assay versus treatment administration
data in primary and secondary cohort
The sensitivities of the investigational assay for the
detection of administered drugs were 93.9% or higher
for all drugs except ETH (Table 2). Specificity, however,
was high for only a few drugs, and several had upper
Fig. 1 Participant Enrollment and Testing
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Table 1 Demographic and clinical characteristics of participants at enrollment
Characteristic MDR/XDR-TB cohort (primary)
Female sex — no./total no. (%) 56/57 (98%)
Median age (range) — yr 33 (22–58)
Time from most recent diagnosis to small hair sample collection (median, IQR) — days 144 (50–337)





Treatment Outcome — no./total no. (%)
Loss to follow-up 14/57 (25%)
Treatment failure 6/57 (11%)
Relapse 3/57 (5%)
Continuing Treatment 18/57 (32%)
Cure 15/57 (26%)
Complete 1/57 (2%)
Table 2 Sensitivity and specificity of the investigational assay, with treatment history as the reference standard





% (95% CI) No. not detected/no. not taking
drugs
% (95% CI) Median (IQR) Median (IQR)
Isoniazid 31/33 93.9 (79.8–
99.3)
12/20 60 (36.1–80.9) 0.99 (0.32–2.21) 0.33 (0.25–
0.46)
Pyrazinamide 54/54 100 (93.3–
100)
0/2 0 (0–84.2) 9.84 (4.52–18.54) 0.26 (0.22–
0.38)
Ethambutol 45/45 100 (92.1–
100)
0/10 0 (0–30.8) 0.92 (0.43–1.53) 0.05 (0.02–
0.35)
Levofloxacin 30/30 100 (88.4–
100)




Moxifloxacin 41/41 100 (91.4–
100)








9.12 (4.20–17.66) 0.16 (0.14–
0.43)
Clofazimine 34/34 100 (89.7–
100)
2/22 9.1 (1.1–29.2) 2.98 (1.39–4.59) 0.20 (0.05–
0.67)
Bedaquiline 27/27 100 (87.2–
100)
7/28 25 (10.7–44.9) 0.90 (0.71–1.46) 0.21 (0.10–
0.35)
Pretomanid 1/1 100 (2.5–100) 55/56 98.2 (90.4–
100)
-c –





a For sensitivity, the reference standard was considered ‘positive’ if the drug was taken for at least 14 days during the hair growth window
b For specificity, the reference standard was considered ‘negative’ if the drug is not taken for any days in the previous 124 days prior to and including the day of
hair collection. For BDQ and CFZ, the reference standard was ‘negative’ if there was no known history of past use of the drug at any time
c Not enough data points for comparison
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95% confidence bounds below 50%. In contrast, specifi-
city as ascertained within the secondary HIV/LTBI
cohort was 100% (95% CI, 88–100%) for all analytes
excepting INH, for which specificity could not be ascer-
tained due to INH treatment among all participants.
Within the primary cohort, the distributions of above-
LOD drug concentrations were substantially lower
among those without known treatment histories (i.e.,
false-positives) relative to those with confirmed treat-
ment histories (i.e., true positives), with the first quartile
among true positives higher than the third quartile
among false positives for PZA, EMB, LFX, MFX, LZD,
CFZ, and BDQ (Table 2).
Discussion
Measuring medication concentrations in small hair sam-
ples can provide a long-term metric of adherence and
exposure. We assessed the diagnostic accuracy of a novel
multi-analyte hair assay for eleven anti-TB drugs used in
RR-TB treatment regimens. In a primary cohort of
patients with extensive drug resistance and multiple
prior TB regimens, our assay identified drug in hair with
high sensitivity but apparent poor specificity. In order to
determine the etiology of the high proportion of “false-
positives” in the primary cohort, we next assessed speci-
ficity in a cohort of patients with a very low likelihood of
exposure to anti-TB drugs other than INH. We deter-
mined that apparent false-positive assays in the primary
cohort were most likely due to prior undocumented
treatment histories. Research studies or clinicians utiliz-
ing hair PK assays for treatment monitoring in similar
populations should note this possibility in interpreting
assay results.
Our observation can be better understood by consider-
ing what is known about how xenobiotics accumulate in
hair. Xenobiotics are thought to incorporate into hair (a
pure collagen matrix in mammals) through passive diffu-
sion into the growing hair follicle via surrounding arter-
ial capillaries, through deposition via sweat and sebum
after emergence from the scalp, and through external
contamination (e.g., through physical contact). For a
given absolute drug exposure and hair growth rate,
incorporation of specific drugs into hair is a function of
basicity, lipophilicity, and melanin content of hair, all of
which increase hair drug concentrations. As an objective
treatment monitoring tool, the major practical advantage
of the hair biomatrix relative to blood or urine is the
extended surveillance window for drug exposure over
prior weeks to months, rather than hours to days [6]. A
heuristic for estimating the period of drug exposure as-
sumes a constant 1 cm/month hair growth rate (e.g., a 2-
cm segment of hair corresponds to a 2 month period of
drug exposure). However, a broader band of positivity
from single doses of drugs have been noted in the
forensic literature [13–15]. This variability in the area
over which incorporated drug can be distributed in the
hair shaft can be due to actual rate of hair growth (range
in healthy subjects of at least 0.3 to 1.8 cm/mo) [15], rate
of axial distribution of drug, and a number of other bio-
logic characteristics.
We found a high sensitivity of our hair assay for all
the DR-TB drugs except for ethionamide (most likely
due to the poor incorporation of ethionamide in hair, as
previously noted) [14]. Although patient management
during the duration of our study in South Africa in-
cluded inpatient treatment of drug-resistant TB, first-
and second-line regimens are often started prior to in-
patient treatment referral. In addition, programmatic
diagnosis of drug-resistant TB can be delayed by to up
to 2 months, during which time patients are often
treated with first-line regimens. A high specificity of our
assay is supported by findings in our post-hoc secondary
cohort, as well as by the finding of substantially lower drug
concentrations among individuals in our primary cohort
without confirmed drug exposure in the hair growth
window. In theory, this indicates that prior treatment
regimens not otherwise discernable could be objectively
delineated through use of our panel assay. Nevertheless,
use of our assay in programmatic settings or in research
settings involving DR-TB retreatment will have to take
account the possibility of prior successive TB treatment
regimens in assessing hair drug concentrations.
An important limitation of our study is that initial
sample collection failed to adequately delineate the prox-
imal from the distal end of the hair thatch; this was later
corrected, and these earlier samples were not used in
our analyses. Additional measures to verify correct label-
ing of small hair samples, or, alternatively, analyzing the
entire hair sample and standardizing by weight, is rec-
ommended. Second, we assessed the diagnostic accuracy
of individual anti-TB drug concentrations above their
limits of detection qualitatively against an inpatient
treatment record gold standard. Although inpatient
treatment records represent a reasonable reference
standard, they may imperfectly represent true drug in-
gestion. Third, we designed a post hoc analysis to exam-
ine an unanticipated decrement in assay specificity for
many drugs. However, we consider this as a co-
publication of two separate sequential studies rather
than as an unplanned subgroup analysis, and thus not
subject to the dangers and limitations typically ascribed
to the latter [16].
Conclusion
In conclusion, we assessed the diagnostic accuracy of an
11-drug RR-TB panel assay to ascertain drug exposure
in small hair samples in a routine care setting. Since hair
concentrations reflect long-term exposure, use of prior
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medications may be reflected in hair even after discon-
tinuation. Among patients with drug-resistant TB, failure
to account for these prior regimens may result in appar-
ent false-positive qualitative and falsely elevated quanti-
tative hair drug levels. Additional investigations
examining the quantitative association of medication
concentrations in small hair samples with RR-TB treat-
ment outcomes are ongoing.
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